Study: 86% of docs cut Zyprexa use

Whoever said there's no such thing as bad publicity never worked in pharma. The latest proof of bad news-related suffering: A new report on antipsychotic drugs finds Janssen's Risperdal and AstraZeneca's Seroquel overtaking Eli Lilly's Zyprexa.

Some 86 percent of doctors have cut their use of Zyprexa because of problems with weight gain and diabetes, the study found. These are the very side effects that captured so much attention late last year, when clinical trial data about them was leaked to The New York Times.

- read this releaseï¾ from research firm Decision Resources

Related Articles:
Lilly ignored Zyprexa safety data on weight, blood sugar. Report
Lilly to pay $500M to settle Zyprexa claims. Report
NIH doctors slam Lilly's marketing tactics. Report

Suggested Articles

Doctors fear that the only drug approved to prevent preterm birth will no longer be available after an FDA advisory committees vote in October.

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

As the drug pricing debate rolls on, biopharma lobbyists are staying busy. Very busy, in fact. PhRMA, for one, spent a record $29 million last year.